| Qinjiang Liu,Youxin Tian,Yaqiong Ni. Scabrous patrinia root inhibits circulating tumor cells in differentiated thyroid carcinoma – a clinical observation. Oncol Transl Med, 2017, 3: 181-184. |
| 墓头回干预分化型甲状腺癌循环肿瘤细胞的临床观察 |
| Scabrous patrinia root inhibits circulating tumor cells in differentiated thyroid carcinoma – a clinical observation |
| Received:April 19, 2017 Revised:October 25, 2017 |
| DOI：10.1007/s10330-017-0226-6 |
| 中文关键词: 墓头回； 回康灵片； 分化型甲状腺癌； 流式细胞术； 循环肿瘤细胞 |
| 英文关键词: scabrous patrinia root; Huikangling; differentiated thyroid carcinoma; flow cytometry; circulating tumor cell |
| 基金项目:甘肃省重点中医药项目 （No. GZK-2010-Z9） |
| Author Name | Affiliation | E-mail | | Qinjiang Liu* | Department of Head and Neck Surgery, Gansu Provincial Cancer Hospital, Lanzhou 730050, China | Email: LIUQJ99@126.com | | Youxin Tian | Department of Head and Neck Surgery, Gansu Provincial Cancer Hospital, Lanzhou 730050, China | | | Yaqiong Ni | Department of Head and Neck Surgery, Gansu Provincial Cancer Hospital, Lanzhou 730050, China | |
|
| Hits: 9724 |
| Download times: 11170 |
| 中文摘要: |
| 摘要 目的 观察墓头回提取物（回康灵片）干预分化型甲状腺癌循环肿瘤细胞的临床效果。方法 对循环肿瘤细胞阳性者87例随机分两组，两组均执行分化型甲状腺癌内分泌抑制治疗标准，口服左甲状腺素钠片。治疗组45例，采用内分泌抑制治疗并加服回康灵片，每片0.4g，0.4×3 /次、3次/日、全部完成口服12周治疗。对照组42例单纯采用内分泌抑制治疗。两组在第4周及12周时采用流式细胞术（FCM）检测分化型甲状腺癌循环肿瘤细胞状况并进行综合分析。结果 服用回康灵片4周时，治疗组循环肿瘤细胞阳性18例（40%）、对照组29例（69%）,两组差异有统计学意义（χ2 =8.49 P＜0.05）。服药12周时，治疗组循环肿瘤细胞阳性7例（15.6%）、对照组17例（44.7%）,差异有统计学意义（χ2 =5.68 P＜0.01）。随访中对照组出现肺转移2例、骨转移1例；治疗组1例出现不伴甲状腺癌复发的颈淋巴结复发。结论 墓头回提取物（回康灵片）对分化型甲状腺癌循环肿瘤细胞有抑制作用，其机制尚需进一步研究。 |
| 英文摘要: |
| Objective To observe the clinical inhibition of circulating tumor cells (CTCs) in differentiated thyroid
carcinoma (DTC) by the extract of scabrous patrinia root (Huikangling).
Methods Eighty-seven DTC patients tested positive for CTCs were randomly divided into two groups;
all patients were treated with oral levothyroxine sodium in accordance with the DTC endocrine inhibition
treatment criteria. Patients (n = 45) in the treatment group were provided the standard endocrine therapy
along with oral Huikangling (0.4 g/tablet, 0.4 g × 3 / time, 3 times / day, 12 weeks). Patients (n = 42) in
the control group were only provided the standard therapy. After 4 and 12 weeks, CTCs in the blood were
detected by flow cytometry.
Results After 4 weeks of oral Huikangling treatment, CTCs were detected in 18 (40%) and 29 (69%)
patients in the treatment and control groups, respectively; the difference was statistically significant (χ2 =
8.49, P < 0.05). After 12 weeks, CTCs were detected in 7 (15.6%) and 17 (44.7%) patients in the treatment
and control groups, respectively; the difference was statistically significant (χ2 = 5.68, P < 0.05). Follow-up
evaluation revealed two patients with lung metastasis and one patient with bone metastasis in the control
group; one patient showed lateral neck lymph node metastasis without local recurrence in the treatment
group.
Conclusion Huikangling treatment reduces the number of CTC-positive DTC cases; however, further
studies are needed to elucidate the underlying mechanisms. |
|
View Full Text
Download reader HTML全文 |
| Close |
|
|
|